Literature DB >> 28432844

Evaluating new HbA1c methods for adoption by the IFCC and NGSP reference networks using international quality targets.

Erna Lenters-Westra1, Emma English1.   

Abstract

BACKGROUND: As a reference laboratory for HbA1c, it is essential to have accurate and precise HbA1c methods covering a range of measurement principles. We report an evaluation of the Abbott Enzymatic (Architect c4000), Roche Gen.3 HbA1c (Cobas c513) and Tosoh G11 using different quality targets.
METHODS: The effect of hemoglobin variants, other potential interferences and the performance in comparison to both the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and the National Glycohemoglobin Standardization Program (NGSP) reference systems was assessed using certified evaluation protocols.
RESULTS: Each of the evaluated HbA1c methods had CVs <3% in SI units and <2% in NGSP units at 46 mmol/mol (6.4%) and 72 mmol/mol (8.7%) and passed the NGSP criteria when compared with six secondary reference measurement procedures (SRMPs). Sigma was 8.6 for Abbott Enzymatic, 3.3 for Roche Cobas c513 and 6.9 for Tosoh G11. No clinically significant interference was detected for the common Hb variants for the three methods.
CONCLUSIONS: All three methods performed well and are suitable for clinical application in the analysis of HbA1c. Partly based on the result of this study, the Abbott Enzymatic method on the Architect c4000 and the Roche Gen.3 HbA1c on the Cobas c513 are now official, certified IFCC and NGSP SRMPs in the IFCC and NGSP networks. Sigma metrics quality criteria presented in a graph distinguish between good and excellent performance.

Entities:  

Keywords:  HbA1c; IFCC; diabetes; method evaluation; sigma metrics

Mesh:

Substances:

Year:  2017        PMID: 28432844     DOI: 10.1515/cclm-2017-0109

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Evaluation of Four HbA1c Point-of-Care Devices Using International Quality Targets: Are They Fit for the Purpose?

Authors:  Erna Lenters-Westra; Emma English
Journal:  J Diabetes Sci Technol       Date:  2018-06-19

2.  Selecting a Risk-Based SQC Procedure for a HbA1c Total QC Plan.

Authors:  Sten A Westgard; Hassan Bayat; James O Westgard
Journal:  J Diabetes Sci Technol       Date:  2017-09-14

3.  Sample transport and/or storage can cause falsely low HbA1c levels in blood cells measured by enzymatic assay.

Authors:  Masafumi Koga; Toshika Okumiya; Midori Ishibashi
Journal:  Diabetol Int       Date:  2019-11-08

4.  Comparison between Sigma metrics in four accredited Egyptian medical laboratories in some biochemical tests: an initiative towards sigma calculation harmonization.

Authors:  Rania El Sharkawy; Sten Westgard; Ahmed M Awad; AbdelKarem Omneya I Ahmed; El Hadidi Iman; Ahmed Gaballah; Eman Shaheen
Journal:  Biochem Med (Zagreb)       Date:  2018-06-15       Impact factor: 2.313

5.  Evaluation of the analytical performances of the Cobas c513 analyser for HbA1c assay.

Authors:  Stéphane Jaisson; Nathalie Leroy; Michel Soulard; Aurore Desmons; Emmanuelle Guillard; Philippe Gillery
Journal:  Biochem Med (Zagreb)       Date:  2018-10-15       Impact factor: 2.313

Review 6.  Expected long-term defect rate of analytical performance in the medical laboratory: Assured Sigma versus observed Sigma.

Authors:  Hassan Bayat
Journal:  Biochem Med (Zagreb)       Date:  2018-06-15       Impact factor: 2.313

7.  Outcomes of 25-Gauge Vitrectomy for Tractional and Nontractional Diabetic Macular Edema with Proliferative Diabetic Retinopathy.

Authors:  Hideaki Someya; Kei Takayama; Masaru Takeuchi; Hiroshi Yokoyama; Takeshi Kimura; Masakazu Morioka; Yoshihiro Takamura; Seiji Sameshima; Tetsuo Ueda; Nahoko Ogata; Maki Tashiro; Shigehiko Kitano; Taiji Sakamoto
Journal:  J Ophthalmol       Date:  2019-12-11       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.